Loading
Adipokines, Inflammation, and Metabolic Diseases / Regulation of Appetite and Obesity · Journal article
Journal of Agricultural and Food Chemistry · August 17, 2026
Encouraging direction, but not yet definitive.
This preclinical study demonstrates that arbutin reduces body weight and improves metabolic and inflammatory markers in obese mice, with evidence mechanistically linking these effects to increased gut microbiota-derived short-chain fatty acids and enrichment of specific bacterial taxa. Functional validation via antibiotic depletion and fecal microbiota transplantation supports a causal microbiota-dependent pathway, but translation to human efficacy remains unestablished.
Preclinical mechanistic study in obese mice with functional validation (antibiotic depletion and fecal microbiota transplantation). Obese mice; specific strain, age, sex, and other eligibility criteria not stated. Intervention: Arbutin (phenolic glycoside); dose and duration not specified in abstract. Compared with: Control diet or untreated obese mice; specific comparator not detailed in abstract.
Arbutin reduced body weight, improved glucose and lipid profiles, and suppressed adipogenic and inflammatory gene expression in obese mice 16S rRNA sequencing showed elevated α-diversity and enrichment of Muribaculaceae and Lactobacillus following arbutin treatment Antibiotic depletion abolished arbutin's antiobesity effects, establishing microbiota dependence
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
This finding suggests a mechanistic pathway by which arbutin might ameliorate obesity-related metabolic dysfunction in humans via microbiota modulation, but efficacy and safety in human subjects have not been demonstrated and require clinical investigation before clinical application.
A mechanistic study in obese mice demonstrating arbutin-induced metabolic and inflammatory improvements through microbiota modulation, supported by functional validation via antibiotic depletion and FMT, but limited to animal model without human efficacy data.
As stated by the source record.
Quoted from the source exactly as published.
This finding suggests a mechanistic pathway by which arbutin might ameliorate obesity-related metabolic dysfunction in humans via microbiota modulation, but efficacy and safety in human subjects have not been demonstrated and require clinical investigation before clinical application.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Abstract Gut microbial dysbiosis drives obesity-related metabolic disorders. This study investigated whether arbutin, a phenolic glycoside, alleviates obesity via gut microbiota modulation. In obese mice, arbutin reduced body weight, improved glucose and lipid profiles, suppressed adipogenic and inflammatory gene expression, and strengthened intestinal barrier integrity. 16S rRNA sequencing revealed elevated α-diversity and enrichment of beneficial genera including Muribaculaceae and Lactobacillus. Antibiotic depletion abolished arbutin’s antiobesity effects, whereas fecal microbiota transplantation from arbutin-treated donors recapitulated metabolic improvements and increased fecal short-chain fatty acids, including acetate, propionate, butyrate, and valerate, in a microbiota-dependent manner. Correlation analysis linked SCFA elevation to Muribaculaceae, Bacteroides, Lachnospiraceae_UCG-001, and Prevotellaceae_NK3B31_group, and KEGG enrichment implicated carbohydrate and lipid metabolism as the primary pathways affected. Collectively, these findings establish that arbutin ameliorates obesity-related inflammation and metabolic disorders via gut microbiota-derived SCFA production.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.